X
[{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocross Launches Global Clinical Trials for AI-based Sarcopenia Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Oncocross","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncocross Expands Collaboration with JW Pharmaceutical on AI Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Oncocross
Filters
Companies By Therapeutic Area
Details:
The companies will identify and verify development possibilities for new indications for first-in-class drug pipeline that JW Pharmaceutical is developing in anticancer and regenerative medicine.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
JW Pharmaceutical Corporation
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration
May 27, 2024
Details:
Oncocross is developing OC514 as a drug-drug combination product designed to prevent or treat sarcopenia and other rare muscular diseases, using Oncocross’ proprietary AI platform RAPTOR AI™.
Lead Product(s):
OC514
Therapeutic Area: Musculoskeletal
Product Name: OC514
Highest Development Status: Phase I/ Phase II
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 10, 2023
Details:
Oncocross obtained Australia’s TGA approval on phase I IND application for OC514, aims to evaluate the safety, pharmacokinetics, and pharmacodynamics for targeting muscular diseases including sarcopenia.
Lead Product(s):
OC514
Therapeutic Area: Musculoskeletal
Product Name: OC514
Highest Development Status: Phase I/ Phase II
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 25, 2022